Credit Suisse’s Progenics Pharmaceuticals Inc PGNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-78,175
| Closed | -$297K | – | 4269 |
|
|
2020
Q1 | $297K | Sell |
78,175
-88,584
| -53% | -$382K | ﹤0.01% | 3436 |
|
|
2019
Q4 | $848K | Buy |
166,759
+111,557
| +202% | +$590K | ﹤0.01% | 3246 |
|
|
2019
Q3 | $279K | Buy |
55,202
+1,282
| +2% | +$6.39K | ﹤0.01% | 3733 |
|
|
2019
Q2 | $333K | Sell |
53,920
-34,600
| -39% | -$167K | ﹤0.01% | 3636 |
|
|
2019
Q1 | $410K | Buy |
88,520
+36,158
| +69% | +$164K | ﹤0.01% | 3446 |
|
|
2018
Q4 | $221K | Sell |
52,362
-26,158
| -33% | -$133K | ﹤0.01% | 3641 |
|
|
2018
Q3 | $492K | Buy |
78,520
+14,253
| +22% | +$109K | ﹤0.01% | 3305 |
|
|
2018
Q2 | $517K | Sell |
64,267
-5,866
| -8% | -$44.8K | ﹤0.01% | 3400 |
|
|
2018
Q1 | $523K | Buy |
70,133
+2,953
| +4% | +$19.6K | ﹤0.01% | 3338 |
|
|
2017
Q4 | $401K | Sell |
67,180
-27,908
| -29% | -$170K | ﹤0.01% | 3527 |
|
|
2017
Q3 | $699K | Sell |
95,088
-21,771
| -19% | -$138K | ﹤0.01% | 3342 |
|
|
2017
Q2 | $793K | Sell |
116,859
-36,460
| -24% | -$269K | ﹤0.01% | 2843 |
|
|
2017
Q1 | $1.45M | Buy |
153,319
+72,706
| +90% | +$726K | ﹤0.01% | 2593 |
|
|
2016
Q4 | $697K | Sell |
80,613
-15,864
| -16% | -$117K | ﹤0.01% | 3270 |
|
|
2016
Q3 | $612K | Buy |
96,477
+13,403
| +16% | +$81K | ﹤0.01% | 3307 |
|
|
2016
Q2 | $351K | Sell |
83,074
-9,397
| -10% | -$45.4K | ﹤0.01% | 3623 |
|
|
2016
Q1 | $404K | Buy |
92,471
+33,333
| +56% | +$148K | ﹤0.01% | 3366 |
|
|
2015
Q4 | $362K | Buy |
59,138
+5,652
| +11% | +$37.1K | ﹤0.01% | 3584 |
|
|
2015
Q3 | $306K | Sell |
53,486
-239,308
| -82% | -$1.84M | ﹤0.01% | 3701 |
|
|
2015
Q2 | $2.19M | Buy |
292,794
+169,980
| +138% | +$1.03M | ﹤0.01% | 2490 |
|
|
2015
Q1 | $734K | Buy |
122,814
+12,629
| +11% | +$79.5K | ﹤0.01% | 3244 |
|
|
2014
Q4 | $833K | Buy |
110,185
+74,411
| +208% | +$445K | ﹤0.01% | 3301 |
|
|
2014
Q3 | $186K | Sell |
35,774
-10,367
| -22% | -$51.7K | ﹤0.01% | 4163 |
|
|
2014
Q2 | $199K | Sell |
46,141
-102,282
| -69% | -$391K | ﹤0.01% | 4369 |
|
|
2014
Q1 | $607K | Sell |
148,423
-111,474
| -43% | -$570K | ﹤0.01% | 3557 |
|
|
2013
Q4 | $1.39M | Buy |
259,897
+31,665
| +14% | +$139K | ﹤0.01% | 3000 |
|
|
2013
Q3 | $1.15M | Sell |
228,232
-24,601
| -10% | -$133K | ﹤0.01% | 2839 |
|
|
2013
Q2 | $1.13M | Buy |
+252,833
| New | +$1.13M | ﹤0.01% | 2700 |
|
Other funds holding PGNX
Credit Suisse's PGNX Position: Q2 2020 in Review
Credit Suisse sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 78,175 shares — an estimated $297K sold.
Credit Suisse first reported a position in PGNX in Q2 2013 and held it in 28 quarters. The position peaked at $2.19M in Q2 2015. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.
- Credit Suisse reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
- Credit Suisse sold 78,175 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $297K.
- Credit Suisse first reported a position in Progenics Pharmaceuticals Inc in Q2 2013 and held it in 28 quarters.
- Credit Suisse's Progenics Pharmaceuticals Inc position peaked at $2.19M in Q2 2015.
- 3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.
Based on Credit Suisse's 13F filing for Q2 2020, filed 12 Aug 2020.